Anti-Kir4.1/KCNJ10 monoclonal antibody
The Alternative Names of target: Kir4.1, KCNJ10,ATP-sensitive inward rectifier potassium channel 10,ATP-dependent inwardly rectifying potassium channel Kir4.1, Inward rectifier K(+) channel Kir1.2, Potassium channel, inwardly rectifying subfamily J member 10,KIR1.2,KIR4.1,SESAME,BIRK-10,KCNJ13-PEN
Pre-made anti-Kir4.1/KCNJ10 monoclonal antibody (mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research.
Go
to Kir4.1/KCNJ10 products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T09423-Ab-1/ GM-Tg-hg-T09423-Ab-2 | Anti-Human Kir4.1/KCNJ10 monoclonal antibody | Human |
GM-Tg-rg-T09423-Ab-1/ GM-Tg-rg-T09423-Ab-2 | Anti-Rat Kir4.1/KCNJ10 monoclonal antibody | Rat |
GM-Tg-mg-T09423-Ab-1/ GM-Tg-mg-T09423-Ab-2 | Anti-Mouse Kir4.1/KCNJ10 monoclonal antibody | Mouse |
GM-Tg-cynog-T09423-Ab-1/ GM-Tg-cynog-T09423-Ab-2 | Anti-Cynomolgus/Rhesus macaque Kir4.1/KCNJ10 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T09423-Ab-1/ GM-Tg-felg-T09423-Ab-2 | Anti-Feline Kir4.1/KCNJ10 monoclonal antibody | Feline |
GM-Tg-cang-T09423-Ab-1/ GM-Tg-cang-T09423-Ab-2 | Anti-Canine Kir4.1/KCNJ10 monoclonal antibody | Canine |
GM-Tg-bovg-T09423-Ab-1/ GM-Tg-bovg-T09423-Ab-2 | Anti-Bovine Kir4.1/KCNJ10 monoclonal antibody | Bovine |
GM-Tg-equg-T09423-Ab-1/ GM-Tg-equg-T09423-Ab-2 | Anti-Equine Kir4.1/KCNJ10 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. |
GM-Tg-hg-T09423-Ab-1/ GM-Tg-hg-T09423-Ab-2;
GM-Tg-rg-T09423-Ab-1/ GM-Tg-rg-T09423-Ab-2;
GM-Tg-mg-T09423-Ab-1/ GM-Tg-mg-T09423-Ab-2; GM-Tg-cynog-T09423-Ab-1/ GM-Tg-cynog-T09423-Ab-2; GM-Tg-felg-T09423-Ab-1/ GM-Tg-felg-T09423-Ab-2; GM-Tg-cang-T09423-Ab-1/ GM-Tg-cang-T09423-Ab-2; GM-Tg-bovg-T09423-Ab-1/ GM-Tg-bovg-T09423-Ab-2; GM-Tg-equg-T09423-Ab-1/ GM-Tg-equg-T09423-Ab-2 |
Products Name | Anti-Kir4.1/KCNJ10 monoclonal antibody |
Format | mab |
Target Name | Kir4.1/KCNJ10 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | Therapeutics Target |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) |
IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-Kir4.1/KCNJ10 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data/case study
Click to get more Data/Case study about the product.
About Gmab
GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.
Comments
No comments yet.